Skip to main content
    X

    Xtant Medical Holdings Inc (XTNT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • AMEX

    $0.27
    -0.00 (-1.31%)

    Market Cap: $38.12M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Xtant Medical Holdings Inc (XTNT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 16, 2026. Financial statements from company filings, amounts in US dollars.

    Xtant Medical Holdings reported revenue of $133.93M for the fiscal year ended Dec 31, 2025, up 14.2% from the year before. That year, net income was $4.97M with a net margin of 3.7%, operating cash flow was $12.55M and free cash flow was $10.16M. The quarter ended Sep 30, 2026 had revenue of $24.29M and net income of -$3.56M.

    Revenue and Margins

    The operating margin was 5.4% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $90.00M, a compound annual rate of 4.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$133.93M+14.2%62.9%5.4%3.7%
    Dec 2024$117.27M+28.4%58.2%-10.3%-14.0%
    Dec 2023$91.30M+57.5%60.8%-11.1%0.7%
    Dec 2022$57.97M+4.9%55.4%-11.7%-14.6%
    Dec 2021$55.26M+3.6%58.8%-7.0%-8.8%
    Dec 2020$53.34M-17.5%64.5%-1.4%-13.2%
    Dec 2019$64.68M-10.4%65.7%-3.5%-12.7%
    Dec 2018$72.20M-12.6%60.2%-83.2%-97.1%
    Dec 2017$82.61M-8.2%60.6%-45.8%-63.4%
    Dec 2016$90.00MN/A69.2%-8.4%-21.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$133.93M$117.27M$91.30M$57.97M$55.26M$53.34M$64.68M$72.20M$82.61M$90.00M
    Cost of revenue$49.65M$49.05M$35.84M$25.83M$22.77M$18.95M$22.17M$28.72M$32.51M$27.71M
    Gross profit$84.27M$68.22M$55.47M$32.14M$32.49M$34.39M$42.52M$43.49M$50.10M$62.29M
    Research and development$2.10M$2.38M$1.34M$915.00K$870.00K$657.00K$932.00K$1.70M$2.44M$3.41M
    Operating income$7.28M-$12.07M-$10.16M-$6.75M-$3.85M-$751.00K-$2.25M-$60.08M-$37.83M-$7.55M
    Net income$4.97M-$16.45M$660.00K-$8.48M-$4.85M-$7.02M-$8.22M-$70.10M-$52.41M-$19.49M
    EBITDA$15.80M-$7.88M$4.93M-$5.46M-$2.52M$1.33M$792.00K-$53.36M-$29.30M$61.43K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$24.29M$23.03M$20.88M$32.36M$33.26M$35.41M$32.90M$31.51M$27.94M$29.94M$27.87M$28.11M
    Gross profit$13.66M$13.33M$11.97M$17.75M$21.99M$24.28M$20.24M$16.02M$16.31M$18.58M$17.30M$17.14M
    Operating income-$3.03M-$9.17M-$2.92M-$944.00K$2.54M$4.62M$1.06M-$1.88M-$3.78M-$2.95M-$3.47M-$3.81M
    Net income-$3.56M-$9.41M-$3.09M$57.00K$1.31M$3.55M$58.00K-$3.16M-$5.02M-$3.86M-$4.40M-$4.30M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $25.38M exceeded cash and equivalents by $8.33M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$94.14M$93.84M$92.61M$60.23M$54.69M$41.47M$43.16M$46.42M$105.70M$144.10M
    Current assets$78.25M$67.12M$64.87M$49.32M$44.33M$31.36M$32.25M$34.68M$39.70M$48.99M
    Cash and equivalents$17.05M$6.20M$5.71M$20.30M$18.24M$2.34M$5.24M$6.80M$2.86M$2.58M
    Total liabilities$43.19M$50.87M$41.26M$26.06M$23.81M$26.95M$87.36M$90.19M$164.40M$151.17M
    Short-term debt$14.36M$12.12M$4.62M$5.71M$3.62M$16.80M$0$852.00K$366.00K$10.69M
    Long-term debt$11.03M$22.04M$17.17M$9.69M$11.79M$0$76.24M$77.94M$137.96M$50.28M
    Shareholder equity$50.95M$42.96M$51.35M$34.17M$30.88M$14.51M-$44.20M-$43.77M-$58.70M-$7.07M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$75.22M$79.67M$78.00M$94.14M$106.32M$103.48M$95.83M$93.84M$98.88M$95.58M$93.93M$92.61M
    Total liabilities$37.96M$39.65M$29.40M$43.19M$55.94M$54.98M$51.96M$50.87M$53.16M$50.57M$46.25M$41.26M
    Cash and equivalents$7.79M$9.87M$12.14M$17.05M$10.40M$6.92M$5.03M$6.20M$6.60M$5.38M$4.55M$5.71M
    Shareholder equity$37.26M$40.02M$48.60M$50.95M$50.38M$48.50M$43.88M$42.96M$45.73M$45.01M$47.68M$51.35M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 81.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$12.55M-$11.90M-$9.52M-$5.34M$439.00K-$731.00K-$413.00K$1.21M-$543.00K-$14.41M
    Capital expenditures$2.38M$4.11M$1.46M$1.76M$2.12M$1.54M$879.00K$624.00K$1.64M$5.83M
    Free cash flow$10.16M-$16.01M-$10.97M-$7.11M-$1.68M-$2.28M-$1.29M$588.00K-$2.18M-$20.24M
    Dividends paidN/AN/AN/AN/A$201.00KN/AN/AN/AN/A$0
    Share repurchasesN/AN/AN/AN/AN/AN/AN/A$3.36M$0N/A
    Investing cash flow$7.90M-$3.73M-$24.78M-$1.56M-$1.89M-$1.30M-$544.00K-$367.00K-$1.61M-$5.82M
    Financing cash flow-$9.57M$16.07M$19.69M$9.02M$17.50M-$861.00K-$603.00K$3.10M$2.43M$16.43M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$855.00K-$7.31M-$2.11M$5.38M$4.61M$1.28M$1.28M$665.00K-$1.72M-$5.09M-$5.75M-$915.00K
    Capital expenditures$389.00K$247.00K$194.00K$395.00K$430.00K$366.00K$1.19M$672.00K$2.10M$564.00K$773.00K$363.00K
    Free cash flow-$1.24M-$7.55M-$2.31M$4.99M$4.18M$910.00K$87.00K-$7.00K-$3.82M-$5.65M-$6.53M-$1.28M
    Last 12 quarters

    Frequently Asked Questions About XTNT

    What is Xtant Medical Holdings' annual revenue?

    Xtant Medical Holdings reported revenue of $133.93M for the fiscal year ended Dec 31, 2025.

    How fast is Xtant Medical Holdings' revenue growing?

    Revenue was up 14.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 32.2%.

    Is Xtant Medical Holdings profitable?

    Yes. Xtant Medical Holdings reported net income of $4.97M for the fiscal year ended Dec 31, 2025, with a net margin of 3.7%.

    How much free cash flow does XTNT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $12.55M minus capital expenditures of $2.38M produced free cash flow of $10.16M.

    How much debt does Xtant Medical Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $11.03M, short-term debt of $14.36M and cash and equivalents of $17.05M.